Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice.
Hee-Yeon ChoSteve SwensonThu Zan TheinWeijun WangNeloni R WijeratneNagore I Marín-RamosJonathan E KatzFlorence M HofmanAxel H SchönthalThomas C ChenPublished in: Neuro-oncology advances (2020)
NEO212 preferentially concentrates in brain tumor tissue over normal brain tissue, and compared to TMZ has a higher brain:plasma ratio, altogether revealing favorable features to encourage its further development as a brain-targeted therapeutic. Its breakdown into well-characterized, long-lived metabolites, in particular AIC and PA, will provide useful equivalents for PK studies during further drug development and clinical trials with NEO212.